| Schedule of Segment Financial Information |
The following table summarizes the reportable segment's financial information (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2025 | | 2024 | | 2025 | | 2024 | | | | | | | | | Revenue | $ | 97,964 | | | $ | 75,400 | | | $ | 191,845 | | | $ | 145,902 | | Less: | | | | | | | | Cost of revenue from sale of therapies | (1,040) | | | (1,707) | | | (1,871) | | | (1,953) | | External research and development (R&D) expenses: | | | | | | | | | PRAME programs | (20,678) | | | (21,932) | | | (37,983) | | | (48,632) | | | Tebentafusp programs | (10,417) | | | (4,557) | | | (18,407) | | | (10,451) | | | Infectious disease programs | (1,325) | | | (1,439) | | | (2,730) | | | (3,685) | | All other external clinical and preclinical costs | (15,253) | | | (4,449) | | | (26,484) | | | (10,948) | | | Total external R&D expenses | (47,673) | | | (32,377) | | | (85,604) | | | (73,716) | | | R&D salaries and other employee-related costs | (12,907) | | | (12,221) | | | (23,950) | | | (21,975) | | Selling, general and administrative (SG&A) salaries and other employee-related costs | (12,827) | | | (10,481) | | | (25,045) | | | (25,321) | | Other SG&A expenses | (22,249) | | | (20,329) | | | (42,921) | | | (37,792) | | Other segment expense, net (a) | (11,568) | | | (9,901) | | | (17,731) | | | (21,197) | | Segment and consolidated net loss | $ | (10,300) | | | $ | (11,616) | | | $ | (5,277) | | | $ | (36,052) | | | | | | | | | |
|